BioCentury
ARTICLE | Financial News

Cubist rating raised

April 18, 2000 7:00 AM UTC

Robertson Stephens analyst Jay Silverman raised his rating on CBST, which is developing its daptomycin antibiotic, to "strong buy" from "buy" with a $66 price target. CBST was up $13.625 (79 percent) ...